Citius Pharma (NASDAQ: CTXR) FDA review data from the phase III trial of MIno-Lok may be a major catalyst for the company shares
Citius Pharma (NASDAQ: CTXR) FDA review data from the phase III trial of MIno-Lok may be a major catalyst for the company shares